Biotricity (BTCY) Competitors $0.50 +0.00 (+0.16%) As of 07/24/2025 12:50 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock BTCY vs. MLSS, NMTC, DXR, TMDIF, PYPD, MODD, NEPH, POCI, COCH, and VVOSShould you be buying Biotricity stock or one of its competitors? The main competitors of Biotricity include Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), Daxor (DXR), Titan Medical (TMDIF), PolyPid (PYPD), Modular Medical (MODD), Nephros (NEPH), Precision Optics (POCI), Envoy Medical (COCH), and Vivos Therapeutics (VVOS). These companies are all part of the "medical equipment" industry. Biotricity vs. Its Competitors Milestone Scientific NeuroOne Medical Technologies Daxor Titan Medical PolyPid Modular Medical Nephros Precision Optics Envoy Medical Vivos Therapeutics Milestone Scientific (NYSE:MLSS) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership. Is MLSS or BTCY more profitable? Milestone Scientific has a net margin of -52.01% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Milestone Scientific's return on equity.Company Net Margins Return on Equity Return on Assets Milestone Scientific-52.01% -60.26% -40.23% Biotricity -80.42%N/A -188.47% Do insiders and institutionals hold more shares of MLSS or BTCY? 5.8% of Milestone Scientific shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 24.8% of Milestone Scientific shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better valuation & earnings, MLSS or BTCY? Milestone Scientific has higher earnings, but lower revenue than Biotricity. Milestone Scientific is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMilestone Scientific$8.61M5.42-$6.93M-$0.07-8.50Biotricity$12.06M1.03-$14.09M-$0.67-0.75 Which has more volatility & risk, MLSS or BTCY? Milestone Scientific has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Biotricity has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Do analysts recommend MLSS or BTCY? Milestone Scientific presently has a consensus target price of $1.25, suggesting a potential upside of 110.08%. Given Milestone Scientific's stronger consensus rating and higher probable upside, research analysts clearly believe Milestone Scientific is more favorable than Biotricity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Milestone Scientific 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Biotricity 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer MLSS or BTCY? In the previous week, Biotricity had 8 more articles in the media than Milestone Scientific. MarketBeat recorded 9 mentions for Biotricity and 1 mentions for Milestone Scientific. Biotricity's average media sentiment score of 0.70 beat Milestone Scientific's score of -1.00 indicating that Biotricity is being referred to more favorably in the news media. Company Overall Sentiment Milestone Scientific Negative Biotricity Positive SummaryMilestone Scientific beats Biotricity on 10 of the 16 factors compared between the two stocks. Get Biotricity News Delivered to You Automatically Sign up to receive the latest news and ratings for BTCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTCY vs. The Competition Export to ExcelMetricBiotricitySurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.45M$66.20M$5.73B$9.47BDividend YieldN/AN/A4.60%3.99%P/E Ratio-0.466.0527.9819.95Price / Sales1.03142.51447.46100.93Price / CashN/A18.4136.5558.97Price / Book-0.387.348.655.90Net Income-$14.09M-$25.32M$3.24B$258.42M7 Day Performance14.84%1.35%3.69%2.11%1 Month Performance31.53%4.16%10.34%12.44%1 Year Performance-35.06%53.27%34.36%19.55% Biotricity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTCYBiotricityN/A$0.50+0.2%N/A-34.7%$12.45M$12.06M-0.4640Analyst RevisionGap DownMLSSMilestone Scientific2.9548 of 5 stars$0.64+1.7%$1.25+94.9%-38.7%$50.32M$8.61M-9.1630NMTCNeuroOne Medical Technologies3.0373 of 5 stars$1.03+14.4%$1.45+40.8%+11.1%$44.84M$3.45M-4.6820High Trading VolumeDXRDaxor3.4473 of 5 stars$9.18+2.0%$25.00+172.3%+5.8%$44.42M$2.13M0.0037TMDIFTitan MedicalN/A$0.38+2.8%N/A+979.5%$43.37M$17.63M-0.3050Gap UpPYPDPolyPid3.1518 of 5 stars$3.76+0.3%$11.80+213.8%+7.2%$38.22MN/A-0.8780Positive NewsMODDModular Medical1.0547 of 5 stars$0.70+0.1%N/A-54.8%$37.92MN/A-1.3720Gap UpNEPHNephros2.4008 of 5 stars$3.51-1.7%$5.00+42.5%+56.4%$37.84M$14.16M50.1530POCIPrecision Optics0.1959 of 5 stars$4.80-1.2%N/A-22.8%$37.26M$19.10M-5.3980COCHEnvoy Medical2.2351 of 5 stars$1.61flat$9.25+474.5%-24.9%$34.34M$220K-1.1734VVOSVivos Therapeutics0.8854 of 5 stars$5.50+1.1%$4.82-12.4%+122.1%$32.04M$14.63M-3.18160Positive News Related Companies and Tools Related Companies Milestone Scientific Alternatives NeuroOne Medical Technologies Alternatives Daxor Alternatives Titan Medical Alternatives PolyPid Alternatives Modular Medical Alternatives Nephros Alternatives Precision Optics Alternatives Envoy Medical Alternatives Vivos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTCY) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThe big winner of Crypto week?It’s Crypto Week at the White House — and the sector is moving from fringe to full-scale adoption. With Bit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotricity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotricity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
